ACTIVE_NOT_RECRUITING

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Talk to us

Conditions

Multiple Myeloma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Official Title

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Quick Facts

Study Start:2012-06-13
Study Completion:2030-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT01838512

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Have documented progression from a prior LoT
  2. * Participants who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
  3. * IMiDs
  4. * PIs
  5. * Combination of IMiD + PI
  6. * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
  7. * Eligible to receive frontline therapy for MM (no prior MM treatment)
  8. * Participants who have initiated treatment for MM with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
  9. * IMiDs
  10. * PIs
  11. * Combination of IMiD + PI
  12. * Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
  1. * Participants who are currently participating in a clinical trial for MM
  2. * Participants who are currently receiving treatment for primary cancer other than MM
  3. * Participants who are not willing or able to provide informed consent
  4. * Participants who are incarcerated
  5. * Participants under compulsory detention for treatment of a physical (eg, infectious) or psychiatric illness

Contacts and Locations

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Local Institution
Birmingham, Alabama, 35213
United States
Local Institute
Goodyear, Arizona, 85338
United States
Local Institution - 0023
Anaheim, California, 92801
United States
Local Institution
Anaheim, California, 92801
United States
Local Institution - 0045
Burbank, California, 91505
United States
Local Institution
Corona, California, 92880
United States
Local Institution - 0048
Downey, California, 90241
United States
Local Institution - 0052
Fountain Valley, California, 92708
United States
Local Institute
Los Angeles, California, 90013
United States
Local Institute
Santa Rosa, California, 95403
United States
Local Institution - 0051
Santa Rosa, California, 95403
United States
Local Institution
Brooksville, Florida, 34613
United States
Local Institution - 0044
Fort Lauderdale, Florida, 33308
United States
Local Institution
Jacksonville, Florida, 32256
United States
Local Institute
Valdosta, Georgia, 31602
United States
Local Institution - 0047
Valdosta, Georgia, 31602
United States
Local Institution
Skokie, Illinois, 60077
United States
Local Institution - 0041
Springfield, Illinois, 62794-9677
United States
Local Institution - 0058
Anderson, Indiana, 46016
United States
Local Institution - 0011
Indianapolis, Indiana, 46237
United States
Local Institution
Indianapolis, Indiana, 46237
United States
Local Institute
Sioux City, Iowa, 51101
United States
Local Institute
Louisville, Kentucky, 40201
United States
Local Institution - 0042
Louisville, Kentucky, 40202
United States
Local Institution
Lafayette, Louisiana, 70503
United States
Local Institution
Shreveport, Louisiana, 71103
United States
Local Institution
Minneapolis, Minnesota, 55404
United States
Local Institution - 0030
Woodbury, Minnesota, 55125
United States
Local Institute
Southaven, Mississippi, 38671
United States
Local Institute
Kansas City, Missouri, 64132
United States
Local Institution - 0050
Kansas City, Missouri, 64132
United States
Local Institution - 0037
Missoula, Missouri, 59802
United States
Local Institute
Saint Joseph, Missouri, 64501
United States
Local Institution - 0020
Springfield, Missouri, 65804
United States
Local Institution
Springfield, Missouri, 65804
United States
Local Institution
St Louis, Missouri, 63110
United States
Local Institute
Missoula, Montana, 59802
United States
Local Institute
Missoula, Montana, 59807
United States
Local Institute
Omaha, Nebraska, 68124
United States
Local Institution - 0024
Omaha, Nebraska, 68124
United States
Local Institution - Canada
No City Provided, New Jersey, 00000
United States
Local Institution - France
No City Provided, New Jersey, 00000
United States
Local Institution - Germany
No City Provided, New Jersey, 00000
United States
Local Institution - Italy
No City Provided, New Jersey, 00000
United States
Local Institution - United Kingdom
No City Provided, New Jersey, 00000
United States
Local Institution - USA
No City Provided, New Jersey, 00000
United States
Local Institution - 0049
Stony Brook, New York, 11794
United States
Local Institute
Cary, North Carolina, 27518
United States
Local Institution - 0033
Cary, North Carolina, 27518
United States
Local Institution - 0010
Gastonia, North Carolina, 28054
United States
Local Institution
Gastonia, North Carolina, 28054
United States
Local Institute
Canton, Ohio, 44718
United States
Local Institution - 0022
Canton, Ohio, 44718
United States
Local Institute
Cleveland, Ohio, 44109-1900
United States
Local Institute
Tulsa, Oklahoma, 74136
United States
Local Institute
Portland, Oregon, 97200
United States
Local Institute
Pottstown, Pennsylvania, 19464
United States
Local Institute
Charleston, South Carolina, 29414
United States
Local Institution - 0016
Charleston, South Carolina, 29414
United States
Local Institute
Knoxville, Tennessee, 37920
United States
Local Institution
Memphis, Tennessee, 38120
United States
Local Institute
Amarillo, Texas, 79106
United States
Local Institute
Corpus Christi, Texas, 78350
United States
Local Institute
Dallas, Texas, 75229
United States
Local Institute
Dallas, Texas, 75231
United States
Local Institution - 0025
Dallas, Texas, 75231
United States
Local Institute
Dallas, Texas, 75390
United States
Local Institution - 0014
Dallas, Texas, 75390
United States
Local Institution - 0032
Garland, Texas, 75042
United States
Local Institute
San Antonio, Texas, 78217
United States
Local Institution - 0027
San Antonio, Texas, 78217
United States
Local Institute
Sherman, Texas, 75090
United States
Local Institute
Seattle, Washington, 98101
United States
Local Institute
Spokane, Washington, 99202
United States
Local Institution - 0026
Spokane, Washington, 99202
United States
Local Institute
Yakima, Washington, 98901
United States
Local Institute
Yakima, Washington, 98902
United States
Local Institution - 0031
Yakima, Washington, 98902
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2012-06-13
Study Completion Date2030-03-31

Study Record Updates

Study Start Date2012-06-13
Study Completion Date2030-03-31

Terms related to this study

Additional Relevant MeSH Terms

  • Multiple Myeloma